Trial Profile
An Open-Label, Multicenter Study Evaluating, The Efficacy, Safety And Pharmacokinetics Of Gabapentin As Adjunctive Therapy In Pediatric Patients With Partial Seizures When Other Antiepileptics Do Not Provide Satisfactory Effects.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Feb 2021
Price :
$35
*
At a glance
- Drugs Gabapentin (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 01 Nov 2011 Actual end date (NCT00620555) is Dec 2010.
- 01 Nov 2011 Actual end date (NCT00620555) is Dec 2010.
- 01 Nov 2011 Actual initiation date (NCT00620555) is May 2008.